TG Therapeutics, Inc.
TGTX
Xếp hạng trong cổ phiếu
#2384
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Giá cổ phiếu
$53.83
Vốn hóa thị trường
$8.24B
Thay đổi (1 ngày)
-1.28%
Thay đổi (1 năm)
52.84%
Quốc gia
US
Giao dịch TG Therapeutics, Inc. (TGTX)
Danh mục
Healthcare
Số lượng cổ phiếu lưu hành của TG Therapeutics, Inc. (TGTX)
Số lượng cổ phiếu lưu hành vào ngày June 2026: 141.77M
Theo các báo cáo tài chính gần đây và giá cổ phiếu của TG Therapeutics, Inc., số lượng cổ phiếu lưu hành hiện tại là 141.77M. Vào cuối December 2023, công ty có 141.96M cổ phiếu lưu hành. Số lượng cổ phiếu lưu hành thường bị ảnh hưởng bởi việc chia tách cổ phiếu và mua lại cổ phiếu.
Lịch sử cổ phiếu lưu hành của TG Therapeutics, Inc. (TGTX) từ 2000 đến 2026
Cổ phiếu lưu hành vào cuối mỗi năm
| Năm | Cổ phiếu lưu hành | Thay đổi |
|---|---|---|
| 2026 (TTM) | 141.77M | -2.44% |
| 2024 | 145.32M | 2.37% |
| 2023 | 141.96M | 4.83% |
| 2022 | 135.41M | 2.41% |
| 2021 | 132.22M | 14.64% |
| 2020 | 115.33M | 30.51% |
| 2019 | 88.37M | 17.10% |
| 2018 | 75.47M | 21.58% |
| 2017 | 62.07M | 26.57% |
| 2016 | 49.04M | 7.44% |
| 2015 | 45.65M | 33.98% |
| 2014 | 34.07M | 34.06% |
| 2013 | 25.41M | 93.80% |
| 2012 | 13.11M | 580.81% |
| 2011 | 1.93M | 4,742.37% |
| 2010 | 39.78K | 58.41% |
| 2009 | 25.11K | 0.00% |
| 2008 | 25.11K | 3.84% |
| 2007 | 24.18K | 13.15% |
| 2006 | 21.37K | 38.05% |
| 2005 | 15.48K | 61.66% |
| 2004 | 9.58K | 20.31% |
| 2003 | 7.96K | 78.92% |
| 2002 | 4.45K | 291.98% |
| 2001 | 1.14K | 160.92% |
| 2000 | 435.00 | 0.00% |
Cổ phiếu lưu hành của các công ty tương tự hoặc đối thủ
| Công ty | Cổ phiếu lưu hành | Chênh lệch | Quốc gia |
|---|---|---|---|
| 253.90M | 79.09% |
US
|
|
| 396.00M | 179.33% |
US
|
|
| 478.91M | 237.81% |
AU
|
|
| 62.19M | -56.14% |
NL
|
|
| - | - |
CH
|
